RESPOND: Improving mental healthcare for labour migrants in the Netherlands during the COVID-19 pandemic: implementation of a stepped care program (DWM/PM+)

Phase 3

Recruiting

• Conditions: psychological symptoms of anxiety, depression and (posttraumatic) stress; anxiety; depression; distress; Psychological symptoms; 10027946

• Registration Number: NL-OMON54380
• Lead Sponsor: Vrije Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 265

Inclusion Criteria

Participants will be eligible to participate in the study (phase 2 (and 3)) if
they meet all of the following criteria:
- 18 years or older;
- Living in the Netherlands as labour migrant
- Having elevated levels of psychological distress (Kessler Psychological
Distress Scale (K10) >15.9).
- Sufficient mastery (written and spoken) of one of the languages the DWM/PM+
intervention is being delivered in (e.g. English, Polish, Romanian).
- Having access to an electronic device with internet access and webcam to
follow the intervention
- Oral and written informed consent before entering the study.

Exclusion Criteria

Potential participants who meet the inclusion criteria will be excluded from
participation in this study (phase 2 (and 3)) if they meet any of the following
criteria:
- Planning to move abroad, e.g. back to their home country or to another
country, before the last quantitative assessment at 2 months after PM+;
- Having acute medical conditions (requiring hospitalisation);
- Imminent suicide risk, or expressed acute needs or protection risks that
require immediate follow-up;
- Having a severe mental disorder (e.g. psychotic disorders,
substance-dependence);
- Having severe cognitive impairment (e.g. severe intellectual disability or
dementia);
- Currently receiving specialised psychological treatment (e.g. EMDR, CBT);
- In case of current psychotropic medication use: being on an unstable dose for
at least 2 months.

Study & Design

• Study Type: Interventional
• Study Design: Not specified